Kite Pharma

About Kite Pharma

Kite Pharma is a leading biotechnology company focused on the development and commercialization of innovative cancer immunotherapy products. Established with a vision to transform the treatment landscape for patients with cancer, Kite Pharma specializes in cell therapy, particularly in the area of chimeric antigen receptor (CAR) T-cell therapy.

The company’s flagship product, Yescarta, is a CAR T-cell therapy that has shown remarkable efficacy in treating certain types of blood cancers. Kite Pharma is committed to advancing its research and development efforts to expand the potential of CAR T-cell therapies for a broader range of cancers.

With a strong emphasis on scientific innovation, Kite Pharma collaborates with leading academic institutions and research organisations to enhance its understanding of cancer biology and improve therapeutic outcomes. The company’s dedicated team of scientists and healthcare professionals work tirelessly to bring cutting-edge therapies from the lab to the clinic.

Kite Pharma operates with a patient-centric approach, ensuring that the needs and experiences of patients are at the forefront of its mission. The company actively engages with healthcare providers and patient advocacy groups to foster a supportive environment for those affected by cancer.

As part of Gilead Sciences, Kite Pharma benefits from a robust infrastructure and resources that enable it to accelerate its research and development initiatives. The company is headquartered in Santa Monica, California, but has a significant presence in the UK, contributing to the global fight against cancer.

In summary, Kite Pharma is dedicated to pioneering advancements in cancer treatment through innovative therapies, collaboration, and a commitment to improving patient outcomes.